ATXS Live signals | Maximize Profits with Getagraph.com

BUY 120840 min ago

@ $14.28

Issued: 14 Feb 2024 @ 12:06

Return: -31.37%

Previous signal: Feb 13 - 14:46

Previous signal: Sell

Return: -0.35 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 11:06):

Stats
Today's Volume	81 708.00
Average Volume	1.03M
Market Cap	538.15M
EPS	$0 ( 2024-03-27 )
Next earnings date	( $-0.350 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.05
ATR14	$0.0180 (0.18%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Agarwal Sunil	Buy	28 200	Stock Option (Right to Buy)
2024-04-05	Agarwal Sunil	Buy	0
2024-04-01	Morabito Christopher	Sell	10 000	Stock Option (Right to Buy)
2024-04-01	Morabito Christopher	Buy	10 000	Common Stock
2024-04-01	Morabito Christopher	Sell	10 000	Common Stock

INSIDER POWER
96.95
Last 97 transactions
Buy: 15 860 733 \| Sell: 474 752

Volume Correlation

Long: 0.48 (neutral)

Short: 0.48 (neutral)

Signal:(36.903) Neutral

Astria Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Astria Therapeutics, Inc. Correlation - Currency/Commodity

0.23
( neutral )

0.04
( neutral )

0.00
( neutral )

0.46
( neutral )

-0.52
( weak negative )

0.52
( weak )

Astria Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.42

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.42

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.43

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-49.16

Financial Reports:

No articles found.

Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Realtime updates for Astria Therapeutics, Inc. [ATXS]

Upcoming Earnings Alert